- Home
- Metabolic Health & Weight Management
- AOD 9604 10mg Vial
AOD 9604 10mg Vial
Vial - lyophilised powderSubcutaneous (SQ)10 mg
AOD 9604 grew out of a simple question about how the body handles fat. It is discussed in body composition research because it comes from a small part of growth hormone, rather than the whole hormone. The interest is metabolic, but human trials have not established it as a weight loss treatment.
Shipping Information
Shipping Information
Free Shipping
Decor Outdoor offers free regular shipping on all orders shipped to residential or commercial addresses within the contiguous United States. Orders are delivered Monday through Friday (excluding holidays).Drop Shipping
We are an online-only luxury furniture and lighting boutique, and do not have a warehouse. Consequently, all orders are drop shipped directly from our manufacturers to your door. If your order includes items from more than one manufacturer, you will receive multiple deliveries. Because we are dependent on the on-hand inventory of our manufacturing partners, some items listed on our site may not actually be available right away. Please call us at 888.784.4644 or via our contact form with any stocking questions and we'll get in touch with the appropriate manufacturer for answers, before you place your order.Ground Shipping
Small parcel items ship regular ground via delivery services such as FedEx, UPS or DHL. Orders typically take 2-3 business days to process and in-stock items will usually be delivered 3-5 days from the date that they ship (depending on origin and destination). If there is a delay, you will be notified by email. No signature is required for standard ground shipping, so you may want to make arrangements to have packages brought inside soon after delivery, if you are unable to receive it in person.
Storage & Handling
Follow the storage instructions on your product label and the information supplied with your batch. Storage and handling requirements vary by product and presentation.
AOD 9604 was developed to explore a small part of growth hormone associated with fat metabolism. Researchers wanted to separate that interest from the wider effects of the full hormone.
Body composition and fat metabolism research. It should not be confused with a proven treatment for weight loss.
The PHI Perspective
An interesting idea still needs results. We explain the original rationale alongside what the human trials found.
For clinician-directed use only where permitted.
How It Works
Research looks at how AOD 9604 may affect the way fat cells store and release energy. It was not designed to replace growth hormone.
What the Research SuggestsLaboratory and animal findings led to human obesity trials. Those trials did not establish a significant weight loss advantage over placebo, so the original metabolic rationale is not a proven weight loss claim.
Evidence level: C. Human trials conducted; efficacy endpoint not met
Storage & Handling
Store lyophilised vial at 2-8 C, protected from light. Do not freeze after reconstitution.
Active compound: AOD-9604 (hGH fragment 176-191)
Mechanism of ActionBelieved to stimulate lipolysis and inhibit lipogenesis in adipose tissue through a beta-3 adrenergic-linked pathway, independent of the growth hormone receptor. Because it lacks the residues required for IGF-1 induction, it does not raise IGF-1 or impair insulin sensitivity in the manner of full-length growth hormone. Separate preclinical work suggests an anabolic effect on chondrocytes.
Clinical Evidence BasePreclinical rodent data support the lipolytic mechanism. Human Phase II obesity trials showed the compound to be well tolerated but did not meet weight-loss endpoints against placebo. Safety has been reviewed favourably in a published toxicology and clinical safety assessment. No regulatory approval for any indication.
Safety & PrecautionsGenerally well tolerated in trials, with adverse events comparable to placebo. Does not appear to raise IGF-1 or affect glucose tolerance. Not to be used in pregnancy or breastfeeding. Caution in active malignancy. Injection-site reactions are the most commonly reported event. Patients should be advised that human efficacy data are not supportive and that clinical benefit is not established.
ContraindicationsPregnancy and breastfeeding; active or recent malignancy; known hypersensitivity. Paediatric use not appropriate.
Literature & ReferencesHeffernan MA et al. Endocrinology, 2001 - lipolytic activity of hGH 177-191. | Stier H et al. Journal of Obesity, 2013 - safety and toxicology review of AOD-9604. | Ng FM et al. Horm Res, 2000 - antilipogenic action of hGH fragments.
Related Products
Ipamorelin Vial
Available in multiple doses
CJC-1295 DAC Vial
Available in multiple doses
